ARCA biopharma, Inc. Form 8-K August 11, 2015 **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2015 (August 11, 2015) ARCA biopharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-22873 36-3855489 (State or Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification No.) 11080 CirclePoint Road, Suite 140, Westminster, CO 80020 (Address of Principal Executive Offices) (Zip Code) (720) 940-2200 (Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- £Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- £Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- £Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- £Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 2 — Financial Information

Item 2.02. Results of Operations and Financial Condition.

On August 11, 2015, ARCA biopharma, Inc. ("ARCA") issued a press release reporting financial results for the second quarter ended June 30, 2015.

The press release is attached hereto as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number Description

Press Release titled "ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments" dated August 11, 2015.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 11, 2015

ARCA biopharma, Inc. (Registrant)

By: /s/ Brian L. Selby

Name: Brian L. Selby

Title: Vice President, Finance and Chief Accounting

Officer

## INDEX TO EXHIBITS

Exhibit

Number Description

99.1 Press Release titled "ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides

Update on Recent Accomplishments" dated August 11, 2015.